Limitation and potential hazards of MAOI's for the treatment of depressive symptoms in abstinent alcoholics
- PMID: 2669469
- DOI: 10.3109/00952998908993413
Limitation and potential hazards of MAOI's for the treatment of depressive symptoms in abstinent alcoholics
Similar articles
-
Adverse reactions to monoamine oxidase inhibitors. Part I. A comparative study.J Clin Psychopharmacol. 1984 Oct;4(5):270-8. J Clin Psychopharmacol. 1984. PMID: 6386898 Clinical Trial.
-
Sustained effects of phenelzine and tranylcypromine on orthostatic challenge in antidepressant-refractory depression.J Clin Psychopharmacol. 2006 Oct;26(5):542-4. doi: 10.1097/01.jcp.0000236657.08663.ae. J Clin Psychopharmacol. 2006. PMID: 16974207 Clinical Trial. No abstract available.
-
L-tryptophan in depression.Biol Psychiatry. 1976 Jun;11(3):295-302. Biol Psychiatry. 1976. PMID: 779855 Clinical Trial.
-
Monoamine oxidase inhibitors in anxiety disorders.J Psychiatr Res. 1988;22 Suppl 1:87-98. doi: 10.1016/0022-3956(88)90070-2. J Psychiatr Res. 1988. PMID: 3050061 Review.
-
'Spontaneous' hypertensive episodes with monoamine oxidase inhibitors.J Clin Psychiatry. 1988 Apr;49(4):163-5. J Clin Psychiatry. 1988. PMID: 3281932 Review.
Cited by
-
Antidepressants for the treatment of people with co-occurring depression and alcohol dependence.Cochrane Database Syst Rev. 2018 Apr 24;4(4):CD008581. doi: 10.1002/14651858.CD008581.pub2. Cochrane Database Syst Rev. 2018. PMID: 29688573 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical